JPWO2023097282A5 - - Google Patents

Info

Publication number
JPWO2023097282A5
JPWO2023097282A5 JP2024529294A JP2024529294A JPWO2023097282A5 JP WO2023097282 A5 JPWO2023097282 A5 JP WO2023097282A5 JP 2024529294 A JP2024529294 A JP 2024529294A JP 2024529294 A JP2024529294 A JP 2024529294A JP WO2023097282 A5 JPWO2023097282 A5 JP WO2023097282A5
Authority
JP
Japan
Prior art keywords
sequence
engineered
nuclease system
ribonucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541402A5 (https=
JP2024541402A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080437 external-priority patent/WO2023097282A1/en
Publication of JP2024541402A publication Critical patent/JP2024541402A/ja
Publication of JP2024541402A5 publication Critical patent/JP2024541402A5/ja
Publication of JPWO2023097282A5 publication Critical patent/JPWO2023097282A5/ja
Pending legal-status Critical Current

Links

JP2024529294A 2021-11-24 2022-11-23 エンドヌクレアーゼ系 Pending JP2024541402A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163282999P 2021-11-24 2021-11-24
US63/282,999 2021-11-24
US202163289981P 2021-12-15 2021-12-15
US63/289,981 2021-12-15
US202263356908P 2022-06-29 2022-06-29
US63/356,908 2022-06-29
PCT/US2022/080437 WO2023097282A1 (en) 2021-11-24 2022-11-23 Endonuclease systems

Publications (3)

Publication Number Publication Date
JP2024541402A JP2024541402A (ja) 2024-11-08
JP2024541402A5 JP2024541402A5 (https=) 2025-12-01
JPWO2023097282A5 true JPWO2023097282A5 (https=) 2025-12-01

Family

ID=86540394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529294A Pending JP2024541402A (ja) 2021-11-24 2022-11-23 エンドヌクレアーゼ系

Country Status (8)

Country Link
US (2) US12410449B2 (https=)
EP (1) EP4437096A4 (https=)
JP (1) JP2024541402A (https=)
KR (1) KR20240110603A (https=)
AU (1) AU2022396533A1 (https=)
CA (1) CA3234233A1 (https=)
MX (1) MX2024006257A (https=)
WO (1) WO2023097282A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
CN121241133A (zh) * 2023-03-31 2025-12-30 阿伯生物技术公司 Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统
WO2025117544A1 (en) * 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
CN117384884B (zh) * 2023-11-30 2024-03-08 辉大(上海)生物科技有限公司 IscB多肽及其用途
CN117511912B (zh) * 2023-12-22 2024-03-29 辉大(上海)生物科技有限公司 IscB多肽、包含其的系统及其用途
WO2025207709A1 (en) * 2024-03-26 2025-10-02 Arbor Biotechnologies, Inc. Reverse transcription-mediated gene editing systems and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CN107849546A (zh) 2015-05-15 2018-03-27 先锋国际良种公司 对cas内切核酸酶系统、pam序列和指导rna元件的快速表征
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
TWI813532B (zh) 2015-06-18 2023-09-01 美商博得學院股份有限公司 降低脱靶效應的crispr酶突變
AU2016370726B2 (en) 2015-12-18 2022-12-08 Danisco Us Inc. Methods and compositions for polymerase II (Pol-II) based guide RNA expression
KR102438360B1 (ko) 2016-03-04 2022-08-31 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
EP3699281A1 (en) 2016-03-11 2020-08-26 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
US12431216B2 (en) 2016-08-17 2025-09-30 Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
JP7306696B2 (ja) 2016-09-30 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Rna誘導型核酸修飾酵素及びその使用方法
SG10201913505WA (en) 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
KR102528384B1 (ko) 2017-01-06 2023-05-02 이뮤너티바이오, 인크. 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포
AU2018240515B2 (en) 2017-03-24 2024-07-25 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
KR102758434B1 (ko) 2017-03-30 2025-01-21 고쿠리츠 다이가쿠 호진 교토 다이가쿠 게놈 편집에 의한 엑손 스키핑 유도 방법
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
EP3625338A4 (en) 2017-05-19 2021-01-20 Tsinghua University CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA
CN107164377A (zh) 2017-06-12 2017-09-15 王小平 基于碱基编辑的基因敲除方法及其应用
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
CN111902536B (zh) 2018-02-15 2024-07-30 西格马-奥尔德里奇有限责任公司 用于真核基因组修饰的改造的cas9系统
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
KR20200130826A (ko) 2018-03-15 2020-11-20 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
AU2019252925A1 (en) 2018-04-13 2020-07-30 Sigma-Aldrich Co. Llc. Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
US11396072B2 (en) 2018-08-20 2022-07-26 Massachusetts Institute Of Technology Robotic manipulation of objects using external contacts
WO2020055941A1 (en) * 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
CN110904045A (zh) 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
JP2022512703A (ja) 2018-10-16 2022-02-07 インテリア セラピューティクス,インコーポレイテッド 免疫療法のための組成物および方法
US20220133790A1 (en) 2019-01-16 2022-05-05 Beam Therapeutics Inc. Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
US20220298494A1 (en) 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US20220220460A1 (en) 2019-02-14 2022-07-14 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
AU2020223370B2 (en) 2019-02-14 2023-04-20 Metagenomi Therapeutics, Inc. Enzymes with RuvC domains
JP2020154564A (ja) 2019-03-19 2020-09-24 富士通株式会社 学習方法、学習プログラムおよび学習装置
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2021097118A1 (en) * 2019-11-12 2021-05-20 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
GB2608292B (en) 2020-03-31 2024-02-14 Metagenomi Inc Class II, type II CRISPR systems
EP4127155A1 (en) * 2020-03-31 2023-02-08 Metagenomi, Inc. Class ii, type ii crispr systems
KR20230021657A (ko) 2020-05-08 2023-02-14 메타지노미, 인크. Ruvc 도메인을 포함하는 효소
EP4165177A4 (en) 2020-05-08 2024-08-28 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
CN112126661B (zh) 2020-09-30 2022-07-22 上海中医药大学 一种高效敲除nk细胞中tigit基因的方法
AU2021364399A1 (en) 2020-10-23 2023-05-11 Massachusetts Institute Of Technology Reprogrammable iscb nucleases and uses thereof
BR112023018948A2 (pt) 2021-03-19 2023-10-17 Metagenomi Inc Edição multiplex com enzimas cas
WO2022232638A2 (en) 2021-04-30 2022-11-03 Metagenomi, Inc. Enzymes with ruvc domains
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
WO2023097262A1 (en) 2021-11-24 2023-06-01 Metagenomi, Inc. Endonuclease systems

Similar Documents

Publication Publication Date Title
JPWO2021202568A5 (https=)
JPWO2020168291A5 (https=)
JPWO2021178933A5 (https=)
GB2605340A (en) Base editing enzymes
US12509718B2 (en) Method of DNA synthesis
Walker et al. DNA sequence around the Escherichia coli unc operon. Completion of the sequence of a 17 kilobase segment containing asnA, oriC, unc, glmS and phoS
KR102168489B1 (ko) CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도
CA3128755C (en) Compositions and methods for treating hemoglobinopathies
GB2625500A (en) Engineered CasX repressor systems
JP2023169897A5 (https=)
US10920215B2 (en) Method for modifying genome sequence to introduce specific mutation to targeted DNA sequence by base-removal reaction, and molecular complex used therein
DK3155099T3 (en) NUCLEASE MEDIATED DNA COLLECTION
FI4118198T3 (fi) Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja käyttömenetelmiä
JP2024009014A5 (https=)
KR20240055073A (ko) 클래스 ii, v형 crispr 시스템
JPWO2022056324A5 (https=)
NZ592082A (en) Promoters for recombinant viral expression
EP3924477A1 (en) Enzymes with ruvc domains
JPWO2023039378A5 (https=)
JPWO2023097282A5 (https=)
JP2020536506A5 (https=)
KR20220124652A (ko) CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
KR20240004618A (ko) Ruvc 도메인을 갖는 효소
JPWO2021217002A5 (https=)
CN105602972B (zh) 基于CRISPR-Cas9体外改造腺病毒载体的方法